Alt a 15 is a new cross-reactive minor allergen of Alternaria alternata

详细信息    查看全文

• 作者：M.F. Gabriel^a ; ^b ; I. Postigo^a ; A. Gutié ; rrez-Rodrí ; guez^a ; E. Suñ ; é ; n^a ; J.A. Guisantes^a ; J. Ferná ; ndez^c ; C.T. Tomaz^b ; J. Martí ; nez^a ; ^{jorge.martinez@ehu.es" class="auth_mail" title="E-mail the corresponding author}
• 关键词：CCD ; cross-reactive carbohydrate determinants ; RACE ; rapid amplification of cDNA ends ; SP ; serine protease ; sIgE ; specific IgE ; SDAP ; structural database of allergenic proteins ; PVDF ; polyvinylidene difluoride
• 刊名：Immunobiology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：221
• 期：2
• 页码：153-160
• 全文大小：1616 K

文摘

Alternaria alternata is one of the most common saprophytes worldwide that is clinically and epidemiologically associated with severe asthma. Therefore, the identification and characterization of all A. alternata allergens are of major clinical importance. This study describes a new cross-reactive A. alternata allergen that was officially named Alt a 15 by the official Allergen Nomenclature Subcommittee. The complete coding region for Alt a 15 was amplified using 5′ and 3′ rapid amplification of cDNA ends and PCR. The recombinant protein was produced in Escherichia coli as a 65-kDa fusion protein, and the protein sequence exhibits high homology with several important fungal allergens. Immunoblotting analyses revealed that IgE antibodies from A. alternata-sensitized patients (n = 59) bound to rAlt a 15 with a prevalence of 10.2%. All patients who presented sIgE to rAlt a 15 were apparently poly-sensitized to A. alternata and C. lunata. The extensive cross-reactivity between A. alternata and C. lunata serine proteases was confirmed using immunoblotting inhibition assays. Overall, Alt a 15 is an important new cross-reactive allergen of A. alternata that explains some allergies to A. alternata without Alt a 1 sensitization and initial diagnostic errors for allergies to Alternaria. This molecule may improve the accuracy of the diagnosis, the understanding, and the management of IgE-mediated fungal diseases.